Vancomycin plus rifampicin for methicillin-resistant Staphylococcus aureus pneumonia benefits only those who have no development of rifampicin resistance during treatment

Critical Care Medicine

Volumn 38, Issue 8, 2010, Pages 1754-

  Tan, Che Kim ^a   Lai, Chih Cheng ^b   Lin, Sheng Hsiang ^c   Hsueh, Po Ren ^d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c Taipei County Hospital   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIUM ISOLATE; DRUG EFFICACY; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 77954934624     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181db7d28     Document Type: Letter

References (3)

1. Jung YJ, Koh Y, Hong S-B, et al: Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38:175-180
2. Ju O, Woolley M, Gordon D: Emergence and spread of rifampicin-resistant, methicillinresistant Staphylococcus aureus during vancomycin-rifampicin combination therapy in an intensive care unit. Eur J Clin Microbiol Infect Dis 2006; 25:61-62
3. Lai CC, Tan CK, Lin SH, et al: Emergence of rifampicin resistance during rifampicincontaining treatment in elderly patients with persistent methicillin-resistant Staphylococcus aureus bacteremia. J Am Geriatr Soc, in press